Monoclonal antibodies against claudin-18 for treatment of cancer
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/00
A61K-039/395
C07K-016/18
A61K-047/68
A61K-051/10
C07K-016/30
A61K-045/06
C07K-016/28
A61K-039/00
출원번호
US-0661846
(2015-03-18)
등록번호
US-10174104
(2019-01-08)
우선권정보
EP-05025657 (2005-11-24)
발명자
/ 주소
Sahin, Ugur
Türeci, Özlem
Usener, Dirk
Fritz, Stefan
Uherek, Christoph
Brandenburg, Gunda
Geppert, Harald-Gerhard
Schröder, Anja Kristina
Thiel, Phillippe
출원인 / 주소
GANYMED PHARMACEUTICALS GMBH
대리인 / 주소
Neal, Gerber & Eisenberg LLP
인용정보
피인용 횟수 :
0인용 특허 :
90
초록▼
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, h
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
대표청구항▼
1. An anti-CLD18A2 antibody that binds to CLD18A2 but not to CLD18A1 and mediates killing of cells expressing CLD18A2, wherein the antibody binds to an epitope comprising amino acid residues within SEQ ID NO: 16, wherein the anti-CLD18A2 antibody comprises a combination of a heavy chain variable reg
1. An anti-CLD18A2 antibody that binds to CLD18A2 but not to CLD18A1 and mediates killing of cells expressing CLD18A2, wherein the antibody binds to an epitope comprising amino acid residues within SEQ ID NO: 16, wherein the anti-CLD18A2 antibody comprises a combination of a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence represented by SEQ ID NO: 135 and the VL comprises an amino acid sequence represented by SEQ ID NO: 142. 2. An anti-CLD18A2 antibody that binds to CLD18A2 but not to CLD18A1 and mediates killing of cells expressing CLD18A2, wherein the antibody binds to an epitope comprising amino acid residues within SEQ ID NO: 16, wherein the anti-CLD18A2 antibody comprises a combination of a heavy chain variable region (VH) and a light chain variable region (VL), wherein the anti-CLD18A2 antibody is a chimerized antibody comprising a VH having an amino acid sequence represented by SEQ ID NO: 135 and a VL having an amino acid sequence represented by SEQ ID NO: 142. 3. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody. 4. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a human IgG1 constant region. 5. A pharmaceutical composition comprising the anti-CLD18A2 antibody of claim 1 and a pharmaceutically acceptable carrier. 6. A method of treating a CLD18-related disease selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder, comprising: administering to a subject the anti-CLD18A2 antibody of claim 1. 7. The method of claim 6, wherein the CLD18-related disease is gastric cancer. 8. The method of claim 6, wherein the CLD18-related disease is pancreatic cancer. 9. The method of claim 6, further comprising administering to the subject a chemotherapeutic agent. 10. The method of claim 6, wherein the anti-CLD18A2 antibody is a chimerized antibody. 11. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a human kappa light chain constant region. 12. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41. 13. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a human IgG1 heavy chain constant region. 14. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 46. 15. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150. 16. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a human IgG1 heavy chain constant region and a human kappa light chain constant region. 17. The anti-CLD18A2 antibody of claim 2, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150 and a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41. 18. A pharmaceutical composition comprising the anti-CLD18A2 antibody of claim 2 and a pharmaceutically acceptable carrier. 19. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 46. 20. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150. 21. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a human IgG1 heavy chain constant region and a human kappa light chain constant region. 22. The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150 and a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41. 23. The method of claim 10, wherein the chimerized antibody comprises a human IgG1 heavy chain constant region and a human kappa light chain constant region. 24. The method of claim 10, wherein the chimerized antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150 and a light chain constant region having an amino acid sequence represented by SEQ ID NO: 41.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (90)
Presta Leonard G. ; Snedecor Bradley R., Altered polypeptides with increased half-life.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies that recognize a polypeptide overexpressed in rectal tumors.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid differentially expressed in melanoma.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid underexpressed in lung tumor.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Türeci, Özlem; Sahin, Ugur; Koslowski, Michael; Fritz, Stefan; Geppert, Harald-Gerhard, Genetic products differentially expressed in tumors and the use thereof.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Fanger Michael W. (Lebanon NH) Guyre Paul M. (Hanover NH) Anderson Clark L. (Columbus OH), Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Polypeptides encoded by a nucleic acid are expressed in esophageal and kidney tumor.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Eaton,Dan L.; Goddard,Audrey; Godowski,Paul J.; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Eaton,Dan L.; Goddard,Audrey; Godowski,Paul J.; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Ferrara, Napoleone; Goddard, Audrey; Godowski, Paul J.; Gurney, Austin L.; Pan, James; Watanabe, Colin K.; Wood, William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.